Company Encyclopedia
View More
name
GeneDx
WGS.US
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
380.10 B
WGS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care ServicesIndustry
Industry Ranking9/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.84%D
    • Profit Margin0.52%C
    • Gross Margin72.40%A
  • Growth ScoreA
    • Revenue YoY50.50%A
    • Net Profit YoY102.49%A
    • Total Assets YoY20.81%A
    • Net Assets YoY42.91%A
  • Cash ScoreA
    • Cash Flow Margin19308.21%A
    • OCF YoY50.50%A
  • Operating ScoreB
    • Turnover0.89B
  • Debt ScoreC
    • Gearing Ratio40.83%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    WGS, WRD, IRDM: Cathie Wood Ramps Up Buying in GeneDx and WeRide, Trims Exposure in Iridium stock

    Cathie Wood's ARK Invest ETFs made significant trades on December 3, 2025, increasing holdings in GeneDx Holdings and WeRide, while reducing exposure in Iridium Communications, Ibotta, and Roku. ARK purchased 23,724 shares of GeneDx and 191,149 shares of WeRide, showing confidence in genomics and self-driving tech. Conversely, ARK sold 214,591 shares of Iridium, 60,304 shares of Ibotta, and 5,380 shares of Roku, indicating a strategic shift away from these companies.

    Tip Ranks·
    US
    WGS
    -1.85%
    US
    WRD
    +1.60%
    Tip Ranks·
    US
    WGS
    -1.85%
    US
    WRD
    +1.60%

    4,300 Shares in GeneDx Holdings Corp. $WGS Purchased by Handelsbanken Fonder AB

    Handelsbanken Fonder AB acquired 4,300 shares of GeneDx Holdings Corp. valued at $397,000 in Q2. Other investors like Westfield Capital and Ensign Peak Advisors also increased their holdings. GeneDx's stock performance shows significant growth, with a 12-month high of $170.75. Analysts have mixed ratings, with some upgrading and others downgrading the stock. Insider trading activity includes significant stock sales by CEO Katherine Stueland and Director Joshua Ruch.

    Market Beat·
    US
    WGS
    -1.85%
    Market Beat·
    US
    WGS
    -1.85%

    Police & Firemen s Retirement System of New Jersey Grows Position in GeneDx Holdings Corp. $WGS

    The Police & Firemen's Retirement System of New Jersey increased its stake in GeneDx Holdings Corp. by 60.6% in Q2, owning 4,261 shares valued at $393,000. Other investors like Geode Capital and PNC Financial also boosted their positions. GeneDx's stock opened at $167.51, with a market cap of $4.84 billion. Analysts have mixed ratings, with a consensus target price of $129.22.

    Market Beat·
    US
    WGS
    -1.85%
    Market Beat·
    US
    WGS
    -1.85%

    Director Joshua Ruch Reports Sale of Genedx Holdings Corp. Common Shares

    Joshua Ruch, Director of Genedx Holdings Corp., has reported the sale of common shares of the company. The news was generated by Public Technologies using AI and is for informational purposes only. The original filing is available via EDGAR, the SEC's system, with Ref. ID: 0000943431-25-000006, dated November 26, 2025.

    Reuters·
    US
    WGS
    -1.85%
    Reuters·
    US
    WGS
    -1.85%

    GeneDx Holdings Corp. (NASDAQ:WGS) Receives Consensus Rating of "Moderate Buy" from Brokerages

    GeneDx Holdings Corp. (NASDAQ:WGS) has received a consensus rating of "Moderate Buy" from eleven brokerages. The stock has a 12-month price target of $129.22. Analysts have recently increased their price targets, with BTIG Research, Canaccord Genuity, and Guggenheim issuing "buy" ratings. Insider transactions include significant stock sales by CEO Katherine Stueland and Director Casdin Capital. Institutional investors have adjusted their stakes, with 61.72% of the stock owned by them. GeneDx's stock opened at $133.63, with a market cap of $3.86 billion.

    Market Beat·
    US
    WGS
    -1.85%
    Market Beat·
    US
    WGS
    -1.85%
    © 2025 Longbridge｜Disclaimer